Data protection rules may block medical progress
In an effort to ban AI tools for facial recognition, the EU risks to block European medical geneticists to recognise genetic diseases.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1325 entries already.
Entries by Thomas Gabrielczyk
NeuVasQ Biotechnologies bags 20m in Series A financing
/in News/by Thomas GabrielczykNeuVasQ Biotechnologies has raised 20m through a Series A investment to advance its technology platform that restores the integrity of the blood-brain barrier in acute neurological disorders.
Coriolis Pharma expands its ATMP development facilities
/in News/by Thomas GabrielczykCoriolis Pharma will launch operations at its currently expanded ATMP development facilities by Q4/2021.
BioverSys AG bags $15m CARB-X funding
/in News/by Thomas GabrielczykCARB-X is funding Swiss pharma company BioVersys with $15.2m to develop a new class of antibiotics to treat infections caused by multidrug-resistant pathogens.
Lonza expands EU production capacity for Moderna vaccine
/in News/by Thomas GabrielczykLonza will expand its production capacity of Modernas mRNA vaccine mRNA1273 at its manufacturing site in Geelen, the Netherlands.
EU approves Biontech/Pfizer vaccine for adolescents
/in News/by Thomas GabrielczykThe European Medicines Agency (EMA) has given the green light for vaccination of adolescents with Biontech’s COVID-19 vaccine Comirnaty (BNT162b2).
Senti Bio and Bluerock ink Regmed collaboration
/in News/by Thomas GabrielczykSenti Biosciences and Bayer subsidiary BlueRock Therapeutics form strategic partnership to combine iPSC and gene circuit-engineered cell therapy platforms.
Pieris in $1.4bn deal with Roche
/in News/by Thomas GabrielczykGerman-US Anticalin specialist Pieris Pharmaceuticals has bagged $20m upfront for a strategic R&D and license agreement with Genentech, the US branch of Swiss Roche AG.
Associations call for acceleration of ATMP trials in Europe
/in News/by Thomas GabrielczykLife science associations are calling for ATMPs to be exempted from the strict EU GMO rules, as their different legal interpretations in EU member states are delaying applications for multicentre […]
COVID-19 med APN01 selected to be tested in ACTIV study
/in News/by Thomas GabrielczykAPEIRON Biologics recombinant ACE2 APN01 has been selected to participate in the US ACTIV study. ACTIV is aimed to speed up development of the best COVID-19 meds.